

David J Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1994760/publications.pdf>

Version: 2024-02-01

220
papers

38,272
citations

11651

70
h-index

2953

189
g-index

220
all docs

220
docs citations

220
times ranked

22263
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Unmeasured, unknown, and hidden: Confounders are not always in plain sight. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, e237-e238. | 0.8 | 4 |
| 2 | Healthcare students support opt-out organ donation for practical and moral reasons. <i>Journal of Medical Ethics</i> , 2022, 48, 522-529. | 1.8 | 0 |
| 3 | Clinical Predictors and Prognosis of Recurrent IgA Nephropathy in the Kidney Allograft. <i>Glomerular Diseases</i> , 2022, 2, 42-53. | 1.0 | 9 |
| 4 | Effect of intensive versus limited monitoring on clinical trial conduct and outcomes: A randomized trial. <i>American Heart Journal</i> , 2022, 243, 77-86. | 2.7 | 2 |
| 5 | Patient-reported vs. physician-estimated symptoms before and after transcatheter aortic valve replacement. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 161-168. | 4.0 | 5 |
| 6 | Racial, Ethnic, and Socioeconomic Disparities in Access to Transcatheter Aortic Valve Replacement Within Major Metropolitan Areas. <i>JAMA Cardiology</i> , 2022, 7, 150. | 6.1 | 37 |
| 7 | Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation. <i>Heart</i> , 2022, , heartjnl-2021-320005. | 2.9 | 14 |
| 8 | Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. <i>Circulation</i> , 2022, 145, 1294-1307. | 1.6 | 11 |
| 9 | Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120009495. | 3.9 | 4 |
| 10 | Anxiety and Depression Following Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2022, 11, e024377. | 3.7 | 3 |
| 11 | Predicting Residual Angina After Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from the OPEN-CTO Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e024056. | 3.7 | 5 |
| 12 | A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation*. <i>Critical Care Medicine</i> , 2022, 50, 1348-1359. | 0.9 | 8 |
| 13 | Response to: Correspondence on 'Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation does need confirmation' by Armoiry and Connock. <i>Heart</i> , 2022, , heartjnl-2022-321180. | 2.9 | 0 |
| 14 | Neutrophil-to-Lymphocyte Ratios in Patients Undergoing Aortic Valve Replacement: The PARTNER Trials and Registries. <i>Journal of the American Heart Association</i> , 2022, 11, . | 3.7 | 10 |
| 15 | Impact of short-term complications of transcatheter aortic valve replacement on longer-term outcomes: results from the STS/ACC Transcatheter Valve Therapy Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 208-213. | 4.0 | 29 |
| 16 | Analysis of Adverse Events Related to Impella Usage (from the Manufacturer and User Facility Device) Tj ETQq0 0 0 rgBT /Overlock 10 Tf | 1.8 | 11 |
| 17 | STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. <i>Annals of Thoracic Surgery</i> , 2021, 111, 701-722. | 1.3 | 91 |
| 18 | Outcomes of retrograde chronic total occlusion percutaneous coronary intervention: A report from the OPEN-CTO registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1162-1173. | 1.7 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. CKJ: Clinical Kidney Journal, 2021, 14, 2075-2084. | 2.9 | 9 |
| 20 | Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: results from the LIBERTY 360Â° trial. Journal of Medical Economics, 2021, 24, 570-580. | 2.1 | 4 |
| 21 | 3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. Journal of the American College of Cardiology, 2021, 77, 1029-1040. | 2.8 | 113 |
| 22 | Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease. Circulation: Heart Failure, 2021, 14, e007564. | 3.9 | 17 |
| 23 | Practical Application of Patient-Reported Health Status Measures for Transcatheter Valve Therapies. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007187. | 2.2 | 14 |
| 24 | # SoMe for # IC : Optimal use of social media in interventional cardiology. Catheterization and Cardiovascular Interventions, 2021, 98, 97-106. | 1.7 | 5 |
| 25 | Variation in Antithrombotic Therapy and Clinical Outcomes in Patients With Preexisting Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2021, 14, e009963. | 3.9 | 7 |
| 26 | Immediate post-procedural functional assessment of percutaneous coronary intervention: current evidence and future directions. European Heart Journal, 2021, 42, 2695-2707. | 2.2 | 34 |
| 27 | Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. European Heart Journal, 2021, 42, 1825-1857. | 2.2 | 342 |
| 28 | The clinical significance of receiving a kidney allograft from deceased donor with chronic histologic changes. Modern Pathology, 2021, 34, 1795-1805. | 5.5 | 3 |
| 29 | Why Is Intravascular Ultrasound Guidance Underutilized in Percutaneous Coronary Intervention?: It Is Not "All About the Benjamins". Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007844. | 2.2 | 5 |
| 30 | Five-Year Outcomes of Endoscopic Sleeve Gastropasty for the Treatment of Obesity. Clinical Gastroenterology and Hepatology, 2021, 19, 1051-1057.e2. | 4.4 | 72 |
| 31 | Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial. Circulation: Cardiovascular Interventions, 2021, 14, e010258. | 3.9 | 9 |
| 32 | Postvaccine Anti-SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients. Kidney International Reports, 2021, 6, 1699-1700. | 0.8 | 37 |
| 33 | Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. Journal of the American College of Cardiology, 2021, 77, 2717-2746. | 2.8 | 416 |
| 34 | Perspectives on COVID-19 vaccination among kidney and pancreas transplant recipients living in New York City. American Journal of Health-System Pharmacy, 2021, 78, 2040-2045. | 1.0 | 21 |
| 35 | Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results From the Transcatheter Valve Therapy Registry. Circulation, 2021, 143, 2229-2240. | 1.6 | 64 |
| 36 | Febrile neutropenia after kidney transplantation. American Journal of Transplantation, 2021, 21, 3436-3443. | 4.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Insulin Sensitivity After Living Donor Nephrectomy. <i>Transplantation Proceedings</i> , 2021, 53, 1858-1864. | 0.6 | 2 |
| 38 | Utilization, Costs, and Outcomes of Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010310. | 3.9 | 6 |
| 39 | Composite Metric for Benchmarking Site Performance in Transcatheter Aortic Valve Replacement: Results From the STS/ACC TVT Registry. <i>Circulation</i> , 2021, 144, 186-194. | 1.6 | 26 |
| 40 | Comparative Effectiveness Research and Cardiovascular Device Registries: Aligning Policy and Methods. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007911. | 2.2 | 4 |
| 41 | Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2021, 78, 314-317. | 1.9 | 34 |
| 42 | Declined Offers for Deceased Donor Kidneys Are Not an Independent Reflection of Organ Quality. <i>Kidney360</i> , 2021, 2, 1807-1818. | 2.1 | 9 |
| 43 | Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021, 42, 4683-4693. | 2.2 | 18 |
| 44 | Prognostic Importance of Health Status Versus Functional Status in Heart Failure and Secondary Mitral Regurgitation. <i>JACC: Heart Failure</i> , 2021, 9, 684-692. | 4.1 | 8 |
| 45 | Kidney allograft biopsy findings after COVID-19. <i>American Journal of Transplantation</i> , 2021, 21, 4032-4042. | 4.7 | 24 |
| 46 | Identification of Frailty Using a Claims-Based Frailty Index in the CoreValve Studies: Findings from the EXTEND-FRAILTY Study. <i>Journal of the American Heart Association</i> , 2021, 10, e022150. | 3.7 | 7 |
| 47 | Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021, 42, 4624-4634. | 2.2 | 54 |
| 48 | Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 1115-1123. | 2.1 | 11 |
| 49 | Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. <i>Circulation</i> , 2021, 143, 479-500. | 1.6 | 132 |
| 50 | Socioeconomic and Geographic Characteristics of Hospitals Establishing Transcatheter Aortic Valve Replacement Programs, 2012-2018. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008260. | 2.2 | 27 |
| 51 | Transporting Results of TAVR Trials to the Real World. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2124-2126. | 2.9 | 1 |
| 52 | Impact of Transcatheter Aortic Valve Replacement on Hospitalization Rates: Insights From Nationwide Readmission Database. <i>Journal of the American Heart Association</i> , 2021, 10, e022910. | 3.7 | 1 |
| 53 | Role of Frailty in Identifying Benefit From Transcatheter Versus Surgical Aortic Valve Replacement. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, . | 2.2 | 14 |
| 54 | Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications. <i>JAMA Cardiology</i> , 2020, 5, 38. | 6.1 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020, 8, 8-23.e18. | 1.6 | 55 |
| 56 | Weighing the potential late benefits versus early hazard associated with bioresorbable vascular scaffolds in percutaneous coronary interventions: a Markov decision analytic model. <i>Coronary Artery Disease</i> , 2020, 31, 230-236. | 0.7 | 0 |
| 57 | Transcatheter Aortic Valve Replacement After Prior Mitral Valve Surgery: Results From the Transcatheter Valve Therapy Registry. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1789-1796. | 1.3 | 2 |
| 58 | Predictors of Clinical Response to Transcatheter Reduction of Secondary Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1007-1014. | 2.8 | 34 |
| 59 | NYHA Functional Classification and Outcomes After Transcatheter Mitral Valve Repair in Heart Failure. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2317-2328. | 2.9 | 33 |
| 60 | Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545. | 2.2 | 93 |
| 61 | Baseline Functional Capacity and Transcatheter Mitral Valve Repair in Heart Failure With Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2331-2341. | 2.9 | 16 |
| 62 | Impact of Deceased Donor Kidney Procurement Biopsy Technique on Histologic Accuracy. <i>Kidney International Reports</i> , 2020, 5, 1906-1913. | 0.8 | 21 |
| 63 | Orthopedic Principles to Facilitate Enhanced Recovery After Cardiac Surgery. <i>Critical Care Clinics</i> , 2020, 36, 617-630. | 2.6 | 6 |
| 64 | Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006511. | 2.2 | 6 |
| 65 | STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2492-2516. | 2.8 | 511 |
| 66 | Association of HLA Typing and Alloimmunity With Posttransplantation Membranous Nephropathy: A Multicenter Case Series. <i>American Journal of Kidney Diseases</i> , 2020, 76, 374-383. | 1.9 | 21 |
| 67 | Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease 2019. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1174-1178. | 4.5 | 81 |
| 68 | Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006182. | 2.2 | 5 |
| 69 | COVID-19 in pancreas transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13359. | 1.7 | 10 |
| 70 | Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1277-1287. | 2.9 | 73 |
| 71 | Health Status Changes and Outcomes in Patients With Heart Failure and Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2099-2106. | 2.8 | 24 |
| 72 | Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1408-1419. | 27.0 | 287 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008226. | 3.9 | 21 |
| 74 | Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill. <i>JAMA Cardiology</i> , 2020, 5, 532. | 6.1 | 8 |
| 75 | Treatment of borderline infiltrates with minimal inflammation in kidney transplant recipients has no effect on allograft or patient outcomes. <i>Clinical Transplantation</i> , 2020, 34, e14019. | 1.6 | 8 |
| 76 | The Effect and Relationship of Frailty Indices on Survival After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 219-231. | 2.9 | 49 |
| 77 | Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 799-809. | 27.0 | 520 |
| 78 | Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2403-2413. | 2.8 | 60 |
| 79 | Ticagrelor With or Without Aspirin After Complex PPCI. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2414-2424. | 2.8 | 122 |
| 80 | TIMER2.0 for analysis of tumor-infiltrating immune cells. <i>Nucleic Acids Research</i> , 2020, 48, W509-W514. | 14.5 | 2,546 |
| 81 | Transcatheter Aortic Valve Replacement in Low-Population Density Areas. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006245. | 2.2 | 17 |
| 82 | Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007258. | 3.9 | 87 |
| 83 | Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1954-1962. | 2.9 | 44 |
| 84 | Association Between Declined Offers of Deceased Donor Kidney Allograft and Outcomes in Kidney Transplant Candidates. <i>JAMA Network Open</i> , 2019, 2, e1910312. | 5.9 | 78 |
| 85 | Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation. <i>Circulation</i> , 2019, 140, 1881-1891. | 1.6 | 51 |
| 86 | Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042. | 27.0 | 683 |
| 87 | In-Hospital Costs and Costs of Complications of Chronic Total Occlusion Angioplasty. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 323-331. | 2.9 | 28 |
| 88 | Patient Characteristics Associated With Antianginal Medication Escalation and De-Escalation Following Chronic Total Occlusion Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005287. | 2.2 | 2 |
| 89 | Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007133. | 3.9 | 17 |
| 90 | Deceased Donor Kidneys Are Harder to Place on the Weekend. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 904-906. | 4.5 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2123-2132. | 2.8 | 94 |
| 92 | Development and Application of a Risk Prediction Model for In-Hospital Stroke After Transcatheter Aortic Valve Replacement: A Report From The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1097-1103. | 1.3 | 49 |
| 93 | The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 459-469. | 2.9 | 179 |
| 94 | Hospital Resource Utilization Before and After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1135-1146. | 2.8 | 26 |
| 95 | Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 651-658. | 2.9 | 19 |
| 96 | Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. <i>New England Journal of Medicine</i> , 2019, 380, 1695-1705. | 27.0 | 3,312 |
| 97 | Regional Disparities in Transplantation With Deceased Donor Kidneys With Kidney Donor Profile Index Less Than 20% Among Candidates With Top 20% Estimated Post Transplant Survival. <i>Progress in Transplantation</i> , 2019, 29, 354-360. | 0.7 | 12 |
| 98 | Change in Hospitalization Rates Following Transcatheter Mitral Valve Repair. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008342. | 3.9 | 6 |
| 99 | Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk. <i>Circulation</i> , 2019, 139, 877-888. | 1.6 | 120 |
| 100 | Effect of Medication Co-payment Vouchers on P2Y ₁₂ Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 44. | 7.4 | 67 |
| 101 | Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2019, 4, 110. | 6.1 | 26 |
| 102 | Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. <i>Kidney International Reports</i> , 2019, 4, 434-446. | 0.8 | 59 |
| 103 | Outcomes of kidney transplant from deceased donors with acute kidney injury and prolonged cold ischemia time - a retrospective cohort study. <i>Transplant International</i> , 2019, 32, 646-657. | 1.6 | 22 |
| 104 | Racial Heterogeneity in Treatment Effects in Peripheral Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004157. | 2.2 | 4 |
| 105 | Association of Stress Test Risk Classification With Health Status After Chronic Total Occlusion Angioplasty (from the Outcomes, Patient Health Status and Efficiency in Chronic Total Occlusion) Trial. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1014-1024. | 1.4 | 14 |
| 106 | Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006144. | 3.9 | 24 |
| 107 | Inclusion of Functional Status Measures in the Risk Adjustment of 30-Day Mortality After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 581-589. | 2.9 | 49 |
| 108 | Association of Transcatheter Mitral Valve Repair With Quality of Life Outcomes at 30 Days and 1 Year. <i>JAMA Cardiology</i> , 2018, 3, 1151. | 6.1 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Periprocedural Stroke and Myocardial Infarction as Risks for Long-Term Mortality in CREST. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004663. | 2.2 | 18 |
| 110 | Transcatheter Mitral-Valve Repair in Patients with Heart Failure. New England Journal of Medicine, 2018, 379, 2307-2318. | 27.0 | 2,079 |
| 111 | Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis ofÂdeÂnovo collapsing glomerulopathy in renalÂallografts. Kidney International, 2018, 94, 1189-1198. | 5.2 | 36 |
| 112 | Impact of a Claims-Based Frailty Indicator on the Prediction of Long-Term Mortality After Transcatheter Aortic Valve Replacement in Medicare Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e005048. | 2.2 | 32 |
| 113 | Predicting Quality of Life at 1 Year After Transcatheter Aortic Valve Replacement in a Real-World Population. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004693. | 2.2 | 35 |
| 114 | Outcomes for potential kidney transplant recipients offered public health service increased risk kidneys: A singleÂ€center experience. Clinical Transplantation, 2018, 32, e13427. | 1.6 | 10 |
| 115 | Association between the â€œTimed Up and Go Testâ€at transplant evaluation and outcomes after kidney transplantation. Clinical Transplantation, 2018, 32, e13410. | 1.6 | 12 |
| 116 | Incidence, Management, and Associated Clinical Outcomes of New-Onset AtrialÂFibrillation Following TranscatheterÂAortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 1746-1756. | 2.9 | 84 |
| 117 | Effect of SAPIEN 3 Transcatheter Valve Implantation on Health Status in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk. JACC: Cardiovascular Interventions, 2018, 11, 1188-1198. | 2.9 | 25 |
| 118 | Transradial Percutaneous Coronary Intervention... Works Great! Less Billing!. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004667. | 2.2 | 2 |
| 119 | Factors leading to the discard of deceased donor kidneys in the United States. Kidney International, 2018, 94, 187-198. | 5.2 | 178 |
| 120 | Quality-of-Life Outcomes After Transcatheter Aortic Valve Replacement in an Unselected Population. JAMA Cardiology, 2017, 2, 409. | 6.1 | 110 |
| 121 | Cell-Free DNA and Active Rejection in Kidney Allografts. Journal of the American Society of Nephrology: JASN, 2017, 28, 2221-2232. | 6.1 | 365 |
| 122 | Economic Outcomes of BioresorbableÂVascular Scaffolds VersusÂEverolimus-Eluting Stents in PatientsÂUndergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2017, 10, 774-782. | 2.9 | 6 |
| 123 | Quality of Life After Surgery or DES in Patients With 3-Vessel or Left Main Disease. Journal of the American College of Cardiology, 2017, 69, 2039-2050. | 2.8 | 63 |
| 124 | Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, . | 2.2 | 8 |
| 125 | Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective. Value in Health Regional Issues, 2017, 12, 74-83. | 1.2 | 11 |
| 126 | The Outcomes, Patient Health Status, and Efficiency IN Chronic Total Occlusion Hybrid Procedures registry. Coronary Artery Disease, 2017, 28, 110-119. | 0.7 | 45 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Association of measured platelet reactivity with changes in P2Y ₁₂ receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the Treatment with ADP receptor inhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. <i>American Heart Journal</i> , 2017, 187, 19-28. | 2.7 | 14 |
| 128 | Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-Main Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3113-3122. | 2.8 | 69 |
| 129 | Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, . | 3.9 | 79 |
| 130 | White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, . | 3.9 | 32 |
| 131 | Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 527-538. | 2.8 | 23 |
| 132 | Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1523-1534. | 2.9 | 234 |
| 133 | Durability of quality of life benefits of transcatheter aortic valve replacement: Long-term results from the CoreValve US extreme risk trial. <i>American Heart Journal</i> , 2017, 194, 39-48. | 2.7 | 30 |
| 134 | Dyspnea Among Patients With Chronic Total Occlusions Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, . | 2.2 | 21 |
| 135 | Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 2017, 377, 2240-2252. | 27.0 | 557 |
| 136 | Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk. <i>JAMA Cardiology</i> , 2017, 2, 837. | 6.1 | 105 |
| 137 | Bioprosthetic Valve Fracture Improves the Hemodynamic Results of Valve-in-Valve Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, . | 3.9 | 173 |
| 138 | Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Tj ETQq0 0 0 rgBT /Overlock 10 2017, 120, 904-910. | 1.6 | 10 |
| 139 | Practical Approaches to Mitigating Economic Barriers to Living Kidney Donation for Patients and Programs. <i>Current Transplantation Reports</i> , 2017, 4, 24-31. | 2.0 | 12 |
| 140 | Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. <i>American Heart Journal</i> , 2017, 183, 62-68. | 2.7 | 60 |
| 141 | Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2017, 69, 367-377. | 2.8 | 405 |
| 142 | Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications. <i>Journal of Applied Laboratory Medicine</i> , The, 2017, 2, 309-321. | 1.3 | 59 |
| 143 | Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1349-1357. | 2.9 | 54 |
| 144 | Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. <i>Journal of the American Heart Association</i> , 2016, 5, . | 3.7 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Health Status Outcomes in Patients With Acute Myocardial Infarction After Rehospitalization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 777-784. | 2.2 | 7 |
| 146 | Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. <i>New England Journal of Medicine</i> , 2016, 374, 1609-1620. | 27.0 | 3,992 |
| 147 | Performance and Validation of the U.S.ÂNCDRÂAcute Kidney Injury Prediction Model in Japan. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1715-1722. | 2.8 | 51 |
| 148 | Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1735. | 7.4 | 759 |
| 149 | The weekend effect alters the procurement and discard rates of deceased donor kidneys in the United States. <i>Kidney International</i> , 2016, 90, 157-163. | 5.2 | 83 |
| 150 | Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. <i>Lancet, The</i> , 2016, 387, 2218-2225. | 13.7 | 899 |
| 151 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2224-2234. | 2.8 | 445 |
| 152 | Clinical and economic outcomes among elderly myocardial infarction survivors in the United States. <i>Cardiovascular Therapeutics</i> , 2016, 34, 450-459. | 2.5 | 18 |
| 153 | Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016, 182, 125-134. | 2.7 | 108 |
| 154 | Diagnosis and Management of Cardiovascular Disease in Advanced and Endâ€Stage Renal Disease. <i>Journal of the American Heart Association</i> , 2016, 5, . | 3.7 | 65 |
| 155 | Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated BalloonsÂVersus Standard Percutaneous Transluminal Angioplasty. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2343-2352. | 2.9 | 50 |
| 156 | Predicting Likelihood for Coronary Artery Bypass Grafting After Nonâ€ST-Elevation Myocardial Infarction: Finding the Best Prediction Model. <i>Annals of Thoracic Surgery</i> , 2016, 102, 1304-1311. | 1.3 | 7 |
| 157 | Relationship of Albuminuria and Renal Artery Stent Outcomes. <i>Hypertension</i> , 2016, 68, 1145-1152. | 2.7 | 50 |
| 158 | Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1868-1877. | 2.8 | 128 |
| 159 | Economic Implications of Transcatheter Aortic Valve Replacement in Patients at Intermediate Surgical Risk. <i>Circulation</i> , 2016, 134, 1416-1418. | 1.6 | 10 |
| 160 | Variation in Hospital Riskâ€Adjusted Mortality Rates Following Transcatheter Aortic Valve Replacement in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 560-565. | 2.2 | 43 |
| 161 | The Norwood operation: Relative effects of surgeon and institutional volumes on outcomes and resource utilization. <i>Cardiology in the Young</i> , 2016, 26, 683-692. | 0.8 | 24 |
| 162 | Benefits and Risks of Extended DualÂAntiplatelet Therapy After Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 138-147. | 2.9 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Surgical Versus Percutaneous Femoral Access for Delivery of Large-Bore Cardiovascular Devices (from the PARTNER Trial). American Journal of Cardiology, 2016, 117, 1643-1650. | 1.6 | 19 |
| 164 | Imaging- and physiology-guided percutaneous coronary intervention without contrast administration in advanced renal failure: a feasibility, safety, and outcome study. European Heart Journal, 2016, 37, 3090-3095. | 2.2 | 158 |
| 165 | Prediction of residual angina after percutaneous coronary intervention. European Heart Journal Quality of Care & Clinical Outcomes, 2015, 1, 23-30. | 4.0 | 30 |
| 166 | The global aHUS registry: methodology and initial patient characteristics. BMC Nephrology, 2015, 16, 207. | 1.8 | 52 |
| 167 | Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. American Heart Journal, 2015, 170, 1140-1150. | 2.7 | 26 |
| 168 | Association of Patient-Reported Health Status With Long-Term Mortality After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2015, 8, e002875. | 3.9 | 47 |
| 169 | Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy. JACC: Cardiovascular Interventions, 2015, 8, 1880-1889. | 2.9 | 87 |
| 170 | Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease. Circulation, 2015, 131, 495-502. | 1.6 | 554 |
| 171 | Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. American Heart Journal, 2015, 169, 222-233.e5. | 2.7 | 34 |
| 172 | Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney International, 2015, 87, 1061-1073. | 5.2 | 342 |
| 173 | Health Status After Transcatheter Aortic Valve Replacement in Patients at Extreme Surgical Risk. JACC: Cardiovascular Interventions, 2015, 8, 315-323. | 2.9 | 76 |
| 174 | Transapical and Transaortic Transcatheter Aortic Valve Replacement in the United States. Annals of Thoracic Surgery, 2015, 100, 1718-1727. | 1.3 | 66 |
| 175 | Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. Circulation: Cardiovascular Interventions, 2015, 8, e001712. | 3.9 | 16 |
| 176 | Relation of Frailty to Outcomes After Transcatheter Aortic Valve Replacement (from the PARTNER) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 | 1.6 | 206 |
| 177 | Supervised Exercise, Stent Revascularization, or Medical Therapy for Claudication Due to Aortoiliac Peripheral Artery Disease. Journal of the American College of Cardiology, 2015, 65, 999-1009. | 2.8 | 225 |
| 178 | Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. Journal of the American College of Cardiology, 2015, 65, 2211-2221. | 2.8 | 240 |
| 179 | Health Status After Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Increased Surgical Risk. JACC: Cardiovascular Interventions, 2015, 8, 1207-1217. | 2.9 | 100 |
| 180 | Temporal Trends in Quality of Life Outcomes After Transapical Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 338-346. | 2.2 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | The Global aHUS Registry: Characteristics of 826 Patients with Atypical Hemolytic Uremic Syndrome. <i>Blood</i> , 2015, 126, 4640-4640. | 1.4 | 0 |
| 182 | Costs of Periprocedural Complications in Patients Treated With Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 829-836. | 3.9 | 76 |
| 183 | Cost-Effectiveness of Supervised Exercise, Stenting, and Optimal Medical Care for Claudication: Results From the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e001233. | 3.7 | 27 |
| 184 | Incidence, Predictors, and Prognostic Impact of Late Bleeding Complications After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2605-2615. | 2.8 | 199 |
| 185 | The Challenges of Success. <i>Circulation</i> , 2014, 130, 1343-1345. | 1.6 | 0 |
| 186 | Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable?. <i>American Heart Journal</i> , 2014, 168, 103-109. | 2.7 | 22 |
| 187 | Bleeding Complications After Surgical Aortic Valve Replacement Compared With Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1100-1109. | 2.8 | 167 |
| 188 | Rethinking Composite End Points in Clinical Trials. <i>Circulation</i> , 2014, 130, 1254-1261. | 1.6 | 96 |
| 189 | Predictors of Poor Outcomes After Transcatheter Aortic Valve Replacement. <i>Circulation</i> , 2014, 129, 2682-2690. | 1.6 | 214 |
| 190 | Cost-Effectiveness of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Bypass Surgery for Patients With 3-Vessel or Left Main Coronary Artery Disease. <i>Circulation</i> , 2014, 130, 1146-1157. | 1.6 | 83 |
| 191 | Early Post-Discharge Bleeding and Antiplatelet Therapy Discontinuation Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1700-1702. | 2.8 | 10 |
| 192 | Baseline Demographics and Characteristics of 466 Patients with Atypical Hemolytic Uremic Syndrome in the Global aHUS Registry. <i>Blood</i> , 2014, 124, 4204-4204. | 1.4 | 0 |
| 193 | Cost-Effectiveness of Percutaneous Coronary Intervention With Drug Eluting Stents Versus Bypass Surgery for Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease. <i>Circulation</i> , 2013, 127, 820-831. | 1.6 | 107 |
| 194 | How to Define a Poor Outcome After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 591-597. | 2.2 | 96 |
| 195 | Quality of Life After PCI vs CABG Among Patients With Diabetes and Multivessel Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1581. | 7.4 | 139 |
| 196 | Use of the Kansas City Cardiomyopathy Questionnaire for Monitoring Health Status in Patients With Aortic Stenosis. <i>Circulation: Heart Failure</i> , 2013, 6, 61-67. | 3.9 | 137 |
| 197 | Grand Challenges in Pediatric Otolaryngology. <i>Frontiers in Pediatrics</i> , 2013, 1, 10. | 1.9 | 3 |
| 198 | Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, S45-S60. | 1.4 | 1,605 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 199 | Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Standard Care Among Inoperable Patients With Severe Aortic Stenosis. <i>Circulation</i> , 2012, 125, 1102-1109. | 1.6 | 266 |
| 200 | State-Transition Modeling. <i>Medical Decision Making</i> , 2012, 32, 690-700. | 2.4 | 231 |
| 201 | Health-Related Quality of Life After Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2012, 60, 548-558. | 2.8 | 256 |
| 202 | Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1438-1454. | 2.8 | 1,560 |
| 203 | Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: One-year results from the SYNTAX trial. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 198-209. | 1.7 | 48 |
| 204 | Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-Year Data.. <i>Blood</i> , 2012, 120, 2084-2084. | 1.4 | 6 |
| 205 | Health-Related Quality of Life After Transcatheter Aortic Valve Replacement in Inoperable Patients With Severe Aortic Stenosis. <i>Circulation</i> , 2011, 124, 1964-1972. | 1.6 | 278 |
| 206 | Quality of Life after PCI with Drug-Eluting Stents or Coronary-Artery Bypass Surgery. <i>New England Journal of Medicine</i> , 2011, 364, 1016-1026. | 27.0 | 242 |
| 207 | Prognostic Implications of Creatine Kinase-MB Elevation After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 474-480. | 3.9 | 45 |
| 208 | Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study. <i>Blood</i> , 2011, 118, 193-193. | 1.4 | 4 |
| 209 | Vascular Hospitalization Rates and Costs in Patients With Peripheral Artery Disease in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 642-651. | 2.2 | 207 |
| 210 | Transplant tourism: a growing phenomenon. <i>Nature Reviews Nephrology</i> , 2009, 5, 128-129. | 9.6 | 7 |
| 211 | The impact of dyspnea on health-related quality of life in patients with coronary artery disease: Results from the PREMIER registry. <i>American Heart Journal</i> , 2009, 157, 1042-1049.e1. | 2.7 | 48 |
| 212 | Clinical End Points in Coronary Stent Trials. <i>Circulation</i> , 2007, 115, 2344-2351. | 1.6 | 4,993 |
| 213 | Standards for Statistical Models Used for Public Reporting of Health Outcomes. <i>Circulation</i> , 2006, 113, 456-462. | 1.6 | 325 |
| 214 | Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses. <i>Circulation</i> , 2004, 110, 508-514. | 1.6 | 212 |
| 215 | Fractional Flow Reserve Compared With Intravascular Ultrasound Guidance for Optimizing Stent Deployment. <i>Circulation</i> , 2001, 104, 1917-1922. | 1.6 | 73 |
| 216 | Impact of Smoking on Clinical and Angiographic Restenosis After Percutaneous Coronary Intervention. <i>Circulation</i> , 2001, 104, 773-778. | 1.6 | 87 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus. <i>Circulation</i> , 2000, 102, E73-86. | 1.6 | 390 |
| 218 | Impact of Smoking on Health-Related Quality of Life After Percutaneous Coronary Revascularization. <i>Circulation</i> , 2000, 102, 1369-1374. | 1.6 | 76 |
| 219 | Admission to Hospitals With On-Site Cardiac Catheterization Facilities. <i>Circulation</i> , 1998, 98, 2010-2016. | 1.6 | 63 |
| 220 | In-Hospital and One-Year Economic Outcomes After Coronary Stenting or Balloon Angioplasty. <i>Circulation</i> , 1995, 92, 2480-2487. | 1.6 | 143 |